SMTL ID : 3m2w.1

Crystal structure of MAPKAK kinase 2 (MK2) complexed with a spiroazetidine-tetracyclic ATP site inhibitor

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.41 Å

Oligo State

monomer

Ligands

1 x L8I: 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one(Non-covalent)

L8I.1: 15 residues within 4Å: Chain A: L.26, G.27, L.28, A.47, K.49, V.74, M.94, E.95, C.96, L.97, D.98, E.146, N.147, L.149, D.163 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:L.26, A:V.74, A:D.98, A:L.149 Hydrogen bonds: A:L.97, A:D.163 Water bridges: A:K.49

1 x MG: MAGNESIUM ION(Non-covalent)

MG.2: 5 residues within 4Å: Chain A: S.68, Q.69, C.70, I.73, R.75 5 PLIP interactions: 3 interactions with chain A, 2 Ligand-Water interactions Metal complexes: A:S.68, A:C.70, A:I.73, H2O.1, H2O.2

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Revesz, L. et al., In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II. Bioorg.Med.Chem.Lett. (2010)

Release Date

2010-07-28

Peptides

MAP kinase-activated protein kinase 2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

MAP kinase-activated protein kinase 2

Related Entries With Identical Sequence